Drugs / VarilrixTM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00792623 | Sep 2003 → Sep 2007 | chickenpox | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00751348 Comparator | Oct 2008 → May 2010 | measles, mumps infectious disease, rubella, varicella zoster infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VarilrixTM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00792623 ↗ |
| Known as | Oka-RIT | “Varilrix(™) [Oka-RIT]; GlaxoSmithKline Vaccines” PMID 25272081 ↗ Oct 2014 |
| Known as | Varilrix | “who received one dose of Priorix™ vaccine together with one dose of Varilrix™ vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper...” NCT00751348 ↗ |
| Modality | Vaccine | “Varilrix™ vaccine” NCT00751348 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT00792623 ↗ |